Healthy Clinical Trial
Official title:
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
The ASI Non-Invasive Arterial Stiffness Screening Device (ASI Device) is an investigational
device under development for the non-invasive assessment of arterial stiffness. The ASI
Device is considerably smaller and more cost effective than its commercially available
counterparts. As the device is readily portable, it is intended to be targeted for use in
the community (or at home), as opposed to within the hospital or clinic setting only.
However, as the device is still under development, it is not known whether it is capable of
determining arterial stiffness with the same sensitivity and consistency as those already in
commercial use. An added variable is the fact the sensor for the ASI Device is located on
the fingertip.
Validation is a prerequisite for obtaining Health Canada approval of devices for diagnostic
purposes. The ASI Device has not been tested against other instruments capable of providing
similar measurements. Therefore, a clinical trial to compare the ASI Device against similar
devices is necessary. The study will compare measurements of arterial stiffness and other
central haemodynamic parameters obtained with the ASI Device against similar measurements
from devices that have already been approved for this purpose by Health Canada/United States
Food and Drug Administration (FDA).
This is an exploratory, proof of concept, open sequential registration comparative study
designed to establish the utility and accuracy of the ASI Non-Invasive Arterial Stiffness
Screening Device (ASI-Device) for the non-invasive vascular assessment of arterial stiffness
relative to other such devices already approved and commercially available in Canada and the
United States.
The pressure exerted from the contraction of the heart creates a wave form, which travels
down the individual's arterial trunk to all parts of the body. The velocity (speed) at which
this wave form travels can serve as an indicator of the degree of arterial stiffness. The
faster the speed of travel of the pulse wave the stiffer the arteries. It has been
demonstrated in other studies that the contour (shape) of the waveform can be affected by
the pulse wave velocity and that analysis of this shape is an acceptable surrogate for
determining the pulse wave velocity and ultimately determining the severity of arterial
stiffness. This method of analysing the contour of the pulse wave to determine the severity
of arterial stiffness is called pulse wave analysis (PWA).
The ASI Device non-invasively measures the severity of arterial stiffness derived through
pulse wave analysis. The study will compare measurements of arterial stiffness and other
central haemodynamic parameters, as derived through pulse wave analysis obtained with the
ASI Device, against similar measurements from the SphygmoCor Px System from AtCor and the
CR-2000 CV Profiler from Hypertension Inc, devices that already have approval for this
purpose by Health Canada and/or the United States Food and Drug Administration.
Three groups of individuals will be sought;
1. Healthy participants (n=25)
2. Persons with Type 2 Diabetes and/or Obesity (n=15)
3. Persons with a diagnosed Cardiovascular/Vascular disease (such as CAD or PAD) (n=15)
Participants will be asked to provide written informed consent prior to participation in the
study. Eligible participants will be asked to attend an in-person visit where they will
undergo the non-invasive vascular testing. Testing will be comprised of:
1. Pulse Wave Analysis using the ASI Device
2. Pulse Wave Analysis using the SphygmoCor Device
3. Pulse Wave Analysis using the CR-2000 CV Profiler
Although pulse wave contour analysis (PWA) has been demonstrated to be an acceptable
surrogate for the assessment of arterial stiffness, Pulse Wave Velocity has been the gold
standard for the assessment of arterial stiffness. As such, the VP-1000, a non-invasive
vascular screening device, will also be used to measure pulse wave velocity.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |